ClinicalTrials.gg
CompletedNCT05396040Updated Feb 25, 2025

School Studies Within the EuCARE Horizon Europe Research Project (EuCARE-SCHOOLS)

An interventional study of LOLLI METHODE in STUDENTS, sponsored by Euresist Network GEIE. Completed at 5 sites in 3 countries. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Euresist Network GEIE · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,373
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Study summary

In this clinical trial, the aim is to determine if regular screening with pooled saliva tests (Lolli-Method) is useful to support school opening and to reduce clusters and attack rates in schools, compared with the standard of care (SoC) regular surveillance based on symptoms and contact tracing by public health departments.

Read the detailed description

In this clinical trial, it will be determined if regular screening with pooled saliva tests (Lolli-Method) is useful to support school opening and to reduce clusters and attack rates in schools, compared with the standard of care (SoC) regular surveillance based on symptoms and contact tracing by public health departments. A multicenter cluster randomised interventional study will be set-up to evaluate the efficacy and applicability of the Lolli-Methode. The study will enrol 440 classes (around 8800 students, teachers and other personnel) from 2 countries, randomised to Lolli-Methode or SoC. Samples from pools will be regularly collected and tested using PCR-based techniques. Test results will be combined with questionnaires filled in by children, parents and schools teachers and principals, concerning social distancing measures implemented and psychological impact of the preventive measures applied during the pandemic. A thorough data analysis will then be performed to understand the applicability of Lolli-Methode to reduce SARS-COV-2 transmission in schools, including incidence, attack rates and cluster analysis. On the other hand, mobility changes and psychological outcomes will be analysed and compared with variables related to SARS-COV-2 transmission. By the end of this study, it will be identified and characterised the applicability of the Lolli-Methode for SARS-COV-2 surveillance, as well as the impact of pandemic preventive measures on children.

An ancillary observational study will be carried out on a different population of schools to study the prevalence of SARS-COV-2, frequencies and size of clusters and attack rates in schools, compared with those of previous waves; to compare the effectiveness of different preventive measures adopted in different schools; to investigate psychological issues in students and teachers related to the pandemic's containment measures.

02

Conditions studied

  • STUDENTS
03

In context

Lead sponsor

Euresist Network GEIE is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kindergartens and school-age children from public or private schools .
  • Enrolled children may be students of classes that have expressed their consent to participate
  • School personnel of participating schools
  • Householders of participating children
  • (for minors the informed consent will be signed by parents or legal guardians) .
  • For minors: will to participate.

Exclusion criteria

Exclusion Criteria:

  • No by schools or children, or the adult participant
  • Suspicion of acute COVID-19 infection:

In case of unknown respiratory infection, no presence of symptoms for at least 48 hours. In case of confirmed SARS-COV-2 infection: inclusion at the earliest 21 days from PCR-positive diagnosis after the onset of potential symptoms and no presence of symptoms for at least 48 hours (according to Standard of Care).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,373 participants (actual)

Study arms

  • Experimental
    LOLLI METHODE

    regular screening with pooled saliva tests (Lolli-Method)

    Procedure: LOLLI METHODE

  • No intervention
    STANDARD OF CARE

    STANDARD OF CARE

Interventions

  • ProcedureLOLLI METHODE

    WEEKLY SCREENING WITH POOLED SALIVA PCR TEST

06

What researchers measure

Primary outcomes

  1. Frequencies of clusters

    Frequencies of clusters in classrooms in which pooled saliva tests (Lolli-Method) are performed in association with standard contact-tracing protocols, compared with classrooms in which SoC protocols are applied.

    Time frame: up to 18 months

  2. Number of participating classes

    Number of classes and of students in the classes that accept to participate in the Lolli-Methode study, if asked, during time

    Time frame: up to 18 months

Secondary outcomes

  1. Transmission/prevalence of SARS-COV-2 in schools by variants

    Transmission/prevalence of SARS-COV-2 in schools by variants, by assessing the proportion of students/staff with positive SARS-COV-2 test identified by pooled saliva tests (Lolli-Method)

    Time frame: up to 18 months

  2. Psychological status of children

    Psychological status of children during coronavirus pandemics: negative and positive feeling during confinement, worries and expectations about school resumption as evaluated by questionnaires.

    Time frame: up to 18 months

07

Study locations

5 sites
  • IEO Istituto Europeo di Oncologia Research Hospital and Treatment Centre
    Milan, Lombardia 20141, Italy
  • Università statale di Milano, Dipartimento di Scienze Biomediche e Cliniche L. Sacco
    Milan, Lombardia 20154, Italy
  • DISTEBA, Università del Salento
    Lecce, Puglia 73100, Italy
  • Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
    Villahermosa, Tabasco 86126, Mexico
  • Global Health and Tropical Medicine; Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa (UNL)
    Lisbon, 1349-008, Portugal
08

References and documents

Publications

  • Ozer EA, Simons LM, Adewumi OM, Fowotade AA, Omoruyi EC, Adeniji JA, Dean TJ, Zayas J, Bhimalli PP, Ash MK, Godzik A, Schneider JR, Mamede JI, Taiwo BO, Hultquist JF, Lorenzo-Redondo R. Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria. medRxiv [Preprint]. 2021 Jul 2:2021.04.09.21255206. doi: 10.1101/2021.04.09.21255206. PubMed 33880483 ↗
  • Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol Cell. 2020 Sep 3;79(5):710-727. doi: 10.1016/j.molcel.2020.07.027. Epub 2020 Aug 4. Erratum In: Mol Cell. 2020 Dec 17;80(6):1136-1138. doi: 10.1016/j.molcel.2020.11.048. PubMed 32853546 ↗
  • Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, Wullimann DJ, Kammann T, Emgard J, Parrot T, Folkesson E; Karolinska COVID-19 Study Group; Rooyackers O, Eriksson LI, Henter JI, Sonnerborg A, Allander T, Albert J, Nielsen M, Klingstrom J, Gredmark-Russ S, Bjorkstrom NK, Sandberg JK, Price DA, Ljunggren HG, Aleman S, Buggert M. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PubMed 32979941 ↗
  • Singh J, Samal J, Kumar V, Sharma J, Agrawal U, Ehtesham NZ, Sundar D, Rahman SA, Hira S, Hasnain SE. Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses. 2021 Mar 9;13(3):439. doi: 10.3390/v13030439. PubMed 33803400 ↗

Individual participant data

Plan to share: Yes — The study is part of a project funded by the European Commission and the project agreement with the Commission affirms that the data and the results will be public

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: after the Study end no time limit was fixed

Access criteria: request to the study coordinator or to he project partners

Data sharing details ↗ · eucareresearch.eu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jun 2024, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
May 27, 2022
StartActual
May 10, 2022
Primary completionActual
Jun 30, 2024
CompletionActual
Aug 1, 2024
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05396040
Lead sponsor
Euresist Network GEIE
Collaborators
University of Salento, Istituto Europeo di Oncologia, University of Milan, University of Lisbon, University of Cologne, Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus"
Responsible party
Sponsor
First posted
May 27, 2022
Start date
May 10, 2022
Primary completion
Jun 30, 2024
Completion
Aug 1, 2024
Last update
Feb 25, 2025

Study contacts

FRANCESCA INCARDONA
study chair · EURESISTE NETWORK GEIE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion